Follow us on twitter

Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study – published online 10/07/2020

Sufei Wang, Pei Ma, Shujing Zhang, Siwei Song, Zhihui Wang, Yanling Ma, Juanjuan Xu, Feng Wu, Limin Duan, Zhengrong Yin, Huilin Luo, Nian Xiong, Man Xu, Tianshu Zeng, Yang Jin

Diabetes is associated with an elevated risk of mortality in most infectious diseases. In this issue, Wang et al ( performed a retrospective study of the relationship between hyperglycaemia and 28-day mortality in coronavirus disease 2019 (COVID-19) patients not previously diagnosed with diabetes. They report that, of 605 COVID-19 patients at two hospitals based in Wuhan, China, 176 (29.1%) had hyperglycemia (≥7.0 mmol/l) at admission without a previous diagnosis of diabetes. These patients had more than twice the risk of death as those with normal blood glucose. Even patients with a CRB score (an effective measure for assessing the severity of pneumonia) that was low or zero were more likely to die if they had increased fasting blood glucose levels. The authors conclude that most COVID-19 patients are prone to glucose metabolic disorders, and that glycaemic testing and addressing elevations in fasting blood glucose at an early stage might help improve the overall outcomes.

All News